Network pharmacology and bioinformatics analysis-based strategy for exploring the mechanisms of luteolin in the treatment of five types of cancer: A retrospective computational study.

Haixu Xu, Wenyu Qiu, Chendong Zhu, Nannan Zhao, Jing Sha

Abstract read

In one paragraph

Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haixu XuSchool of Food and Biology Engineering, Xuzhou University of Technology, China.ORCID 0009-0008-0608-3202

Wenyu QiuSchool of Food and Biology Engineering, Xuzhou University of Technology, China.

Chendong ZhuSchool of Food and Biology Engineering, Xuzhou University of Technology, China.

Nannan ZhaoSchool of Food and Biology Engineering, Xuzhou University of Technology, China.

Jing ShaDepartment of Gynecology and Obstetrics, Xuzhou Central Hospital, Southeast University, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveLuteolin, a natural flavonoid, exhibits anticancer effects; however, its mechanisms of action are unclear.MethodsThis retrospective computational study combined network pharmacology, molecular docking, and molecular dynamics simulation to explore luteolin's anticancer mechanisms in five types of cancers, including breast, lung, colorectal, gastric, and liver cancers. Network pharmacology helps uncover multi-target interactions in complex diseases. Public databases were used to build compound-target, target-disease, and protein-protein interaction networks. Molecular docking and dynamics simulations validated luteolin's binding to AKT1. The Clinical Proteomic Tumor Analysis Consortium dataset and Human Protein Atlas database were used to assess AKT1 expression in cancer versus normal tissues.ResultsTopological analysis identified

Indexed as

Computational BiologyLuteolinNeoplasmsNetwork PharmacologyGene Expression Regulation, NeoplasticHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein Interaction MapsProteomicsProto-Oncogene Proteins c-aktRetrospective StudiesSignal TransductionAKT1 protein, humanLuteolinProto-Oncogene Proteins c-aktAKT1cancer therapyLuteolinmolecular docking and dynamicsnetwork pharmacology

Identifiers

PMID42343650

DOI10.1177/03000605261460317

PMCPMC13309665

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.